Yingxi Intelligent Technology (Shanghai) Co. Ltd. has identified substituted monocyclic or bicyclic heterocyclic compounds acting as fibroblast growth factor receptor (FGFR) inhibitors and reported to be useful for the treatment of asthma, cancer, chronic heart failure, chronic obstructive pulmonary disease, rheumatoid arthritis, inflammation, autoimmune and Parkinson’s disease, among others.
The FDA has awarded orphan drug designation to HL-001, a novel lysophosphatidic acid receptor-1 (LPA1) antagonist being developed for idiopathic pulmonary fibrosis (IPF) by Ube Corp. and Hilung Inc.
ΔF508 is the most prevalent mutation detected in patients with cystic fibrosis (CF), and it causes a loss of F508 within CFTR’s first nucleotide binding domain (NBD1). Researchers from Sionna Therapeutics Inc. recently reported the discovery and preclinical evaluation of novel small-molecule CFTR NBD1 stabilizers and CFTR assembly correctors as potential new agents for the treatment of CF.
Anoat Therapeutics has raised €2 million (US$2.17 million) in seed funding to develop novel therapies for cystic fibrosis. The financing comes from a seed funding partnership between Adbio Partners SAS and Inserm Transfert SA.
Researchers from F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have synthesized NLRP3 inflammasome inhibitors reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease, Parkinson’s disease and Alzheimer’s disease.
At the recent EAACI meeting, researchers presented preclinical data for the inflammasome inhibitor OLT-1177 (dapansutrile), which is being evaluated by Olatec Therapeutics LLC for the treatment of inflammatory diseases.
Another brick in the ambitious Human Cell Atlas initiative has been put into place with the publication of the largest and most comprehensive cell map of the human lung. The open and freely available atlas catalogs the diversity of cells in the lung, including rare and previously undescribed cell types.
Bronchiectasis is an irreversible chronic respiratory condition arising from secondary infections that presents as chronic cough with daily purulent sputum due to a permanent abnormal widening of bronchi.
Researchers from Structure Therapeutics Inc. recently presented details on the discovery and preclinical evaluation of two new apelin receptor (APJ, APLNR) agonists – ANPA-0073 and ANPA-0137 – being developed for the treatment of pulmonary diseases.
Liminal Biosciences Inc. has nominated a lead preclinical candidate, LMNL-6326, from its oxoeicosanoid receptor 1 (OXER1) antagonist program, targeting the treatment of eosinophil-driven diseases such as eosinophilic asthma and atopic dermatitis.
RSS
